CMCatherine A. McCall

Catherine A. McCall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Catherine A. McCall has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Management of shift work disorder: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment

    by Kenneth P. Wright, Sabra M. Abbott, Liza Ashbrook, Christopher L. Drake, Erin Flynn-Evans, Sarah Framnes-DeBoer, Uzma Kazmi, Kelly Keeler, Catherine McCall, Rebecca Morgan, et al.

    Introduction The purpose of this systematic review is to provide supporting evidence for a clinical practice guideline on the treatment of adults with shift work disorder (SWD). Methods The American Academy of Sleep Medicine commissioned a task force of six experts in sleep and circadian medicine. A systematic review was conducted to identify randomized controlled trials, observational studies, and treatment trials in which treatments for the symptoms of excessive sleepiness and/or sleep disturbance/insomnia in adults with SWD, and for circadian adaptation to shift work schedules was tested. Evidence from controlled laboratory trials of simulated shift work and of field-based trials of shift workers with and without a diagnosis of SWD was included. Statistical analyses were performed to determine the significance of critical and important outcomes and clinically meaningful thresholds were set to determine the clinical relevance of treatments on the outcomes examined, where possible. Finally, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence for making recommendations. Results The literature search resulted in 3,045 articles; 118 studies provided data suitable for statistical analyses. The task force provided a detailed summary of the evidence along with the quality of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations.


  • Open Access

    Management of shift work disorder: an American Academy of Sleep Medicine clinical practice guideline

    by Kenneth P. Wright, Sabra M. Abbott, Liza Ashbrook, Christopher L. Drake, Erin Flynn-Evans, Sarah Framnes-DeBoer, Uzma Kazmi, Kelly Keeler, Catherine McCall, Rebecca Morgan, et al.

    Introduction This guideline establishes recommendations for the treatment of SWD. Methods The American Academy of Sleep Medicine (AASM) commissioned a task force of experts in sleep and circadian medicine to develop recommendations and assign strengths based on a systematic review of the literature and an assessment of the evidence using the GRADE process. The task force summarized the relevant literature and the quality of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations supporting the recommendations. The AASM Board of Directors approved the final recommendations. Recommendations The following recommendations are intended as a guide for clinicians in choosing specific treatment(s) for symptoms of excessive sleepiness and/or insomnia, and for circadian adaptation in adults with SWD. Each recommendation statement is assigned a strength (e.g., “Strong” or “Conditional”). For SWD, there were only “conditional” recommendations for or against (i.e., “We suggest…”) and those requiring the clinician to use clinical knowledge and experience and consider the individual patient’s values and preferences to determine the best course of action. Interventions in recommendation statements were compared to no treatment. Adults with SWD with symptoms of excessive sleepiness associated with work schedule: 1. In adults with SWD with excessive sleepiness, the AASM suggests the use of armodafinil or modafinil taken 30 to 60 minutes prior to the night shift over no armodafinil or modafinil (Conditional recommendation, moderate certainty of evidence). 2. In adults with SWD with excessive sleepiness, the AASM suggests the use of bright light over no bright light during the night shift (Conditional recommendation, very low certainty of evidence). Remark: Individuals with SWD who exhibit insomnia and daytime function impairments may also benefit from using bright light during their night shift. 3. In adults with SWD with excessive sleepiness, the AASM suggests the use of caffeine taken prior to and/or during the night shift over no caffeine (Conditional recommendation, very low certainty of evidence). Remark: Caffeine intake close to bedtime can disrupt sleep onset and quality, which may exacerbate symptoms of SWD. 4. In adults with SWD with excessive sleepiness, the AASM suggests the use of a clockwise rotating shift schedule over a counterclockwise rotating shift schedule (Conditional recommendation, very low certainty of evidence). 5. In adults with SWD with excessive sleepiness, the AASM suggests taking a nap over no nap prior to the night shift (Conditional recommendation, very low certainty of evidence). Remark: Sleep inertia occurring soon after the nap may temporarily increase sleepiness, decrease cognitive performance, and increase accident risk. Allowing adequate time for resolution of sleep inertia prior to driving or performing other safety-sensitive behaviors may be needed to reduce these risks. 6. In adults with SWD with excessive sleepiness, the AASM suggests either not eating or eating a snack rather than eating a full meal during the night shift (Conditional recommendation, low certainty of evidence). 7. In adults with SWD with excessive sleepiness, the AASM suggests the combination of caffeine and bright light over the combination of no caffeine and no bright light (Conditional recommendation, very low certainty of evidence). Remark: Caffeine intake close to bedtime can disrupt sleep onset and quality, which may exacerbate symptoms of SWD. 8. In adults with SWD with excessive sleepiness, the AASM suggests the combination of taking a nap and caffeine over the combination of no nap and no caffeine prior to the night shift (Conditional recommendation, very low certainty of evidence). Adults with SWD with sleep disturbance/insomnia: 9. In adults with SWD with daytime sleep disturbance/insomnia the AASM suggests the use of CBT-I over no CBT-I (Conditional recommendation, very low certainty of evidence). 10. In adults with SWD with daytime sleep disturbance/insomnia following the night shift, the AASM suggests the use of melatonin over no melatonin (Conditional recommendation, very low certainty of evidence). 11. In adults with SWD with sleep disturbance/insomnia, when transitioning from daytime to nighttime sleep, the AASM suggests the use of melatonin over no melatonin for night sleep following shift work (Conditional recommendation, low certainty of evidence). 12. In adults with SWD who desire to take a nap prior to the first night shift, the AASM suggests the use of melatonin over no melatonin prior to the nap (Conditional recommendation, very low certainty of evidence). Remark: Melatonin may temporarily increase sleepiness, decrease cognitive performance, and increase accident risk. Allowing adequate time for resolution of sleepiness prior to driving, returning to work or performing other safety-sensitive behaviors may be needed to reduce these risks. 13. In adults with SWD with daytime sleep disturbance/insomnia, the AASM suggests the use of ramelteon or other melatonin receptor agonists over no melatonin receptor agonist (Conditional recommendation, low certainty of evidence). 14. In adults with SWD with daytime sleep disturbance/insomnia, the AASM suggests the use of suvorexant or other dual orexin receptor antagonists over no dual orexin receptor antagonists (Conditional recommendation, low certainty of evidence). 15. In adults with SWD with daytime sleep disturbance/insomnia, the AASM suggests against the use of triazolam and other benzodiazepines (conditional recommendation, very low certainty of evidence). Adults with SWD seeking circadian adaptation: 16. In adults with SWD seeking circadian adaptation to the night shift, the AASM suggests the use of bright light over no bright light during the night shift (Conditional recommendation, very low certainty). Remark: For individuals who work rotating or frequently changing shifts, circadian adaptation is not a realistic goal of treatment and therefore they would not be expected to benefit from this intervention. The evidence supporting this recommendation came from studies in which individuals reached partial circadian adaptation to the night shift. 17. In adults with SWD seeking circadian adaptation to the night shift, the AASM suggests the combination of bright light at night and fixed daytime sleep timing over the combination of no bright light and no fixed sleep timing (Conditional recommendation, very low certainty of evidence). Remark: For individuals who work rotating or frequently changing shifts, circadian adaptation is not a realistic goal of treatment and therefore they would not be expected to benefit from this intervention. The evidence supporting this recommendation came from studies in which individuals reached partial circadian adaptation to the night shift. 18. In adults with SWD seeking circadian adaptation to the night shift, the AASM suggests the combination of bright light at night, fixed daytime sleep timing, and reduced-light-transmittance glasses in the morning over the combination of no bright light, no fixed sleep timing, and no reduced-light-transmittance glasses (Conditional recommendation, very low certainty of evidence). Remark 1 : For individuals who work rotating or frequently changing shifts, circadian adaptation is not a realistic goal of treatment and therefore they would not be expected to benefit from this intervention. The evidence supporting this recommendation came from studies in which individuals reached partial circadian adaptation to the night shift. Remark 2: Attention to driving safety is important when wearing reduced-light-transmittance glasses. Other considerations for adults with SWD: 19. In adults with SWD who are working either an 8-hour or 12-hour night shift, the AASM does not suggest working one shift duration over the other (Conditional recommendation, very low certainty of evidence). Remark: This recommendation does not consider other shift durations, rotation, or the number of consecutive shifts. This guideline did not look at shift durations exceeding 12 hours. The total number of hours worked per week ranged from 36 to 52.

  • Open Access

    Impact of Prior History of Traumatic Stress on Autonomic and Multi-System Symptoms Following COVID-19 Infection

    by Rebecca C. Hendrickson, Christine S. Cheah, Marlene L. Tai, Kathleen F. Pagulayan, Katharine J. Liang, Catherine A. McCall, Abigail G. Schindler, Kimberly L. Hart, Aaron F. Rosser, John C. Oakley

    Background: Persistent symptoms of autonomic dysregulation are common after COVID-19 infection and may result from alterations in central and/or peripheral autonomic regulatory processes. Traumatic stress can cause persistent alterations in autonomic function, potentially changing the response to future traumatic or physiologic stressors. However, the relationship between prior history of traumatic stress and autonomic symptom burden after COVID-19 infection has not been explored. Objectives: Examine the potential for additive and/or interactive effects of traumatic stress and COVID-19 infection on autonomic symptom burden, and compare this with other common post-acute sequelae of COVID-19 (PASC) symptom domains. Design: Observational, self-report, single time-point online assessment. Participants: 404 United States adults with (N = 289) and without (N = 112) a self-reported history of COVID-19 infection. Main Outcomes and Measures: Autonomic symptom burden (Composite Autonomic Symptom Score [COMPASS 31]), lifetime traumatic stressors (Life Events Checklist), posttraumatic stress disorder (PTSD Checklist-5), self-reported neurocognitive functioning (Neuro-QoL), insomnia (Insomnia Severity Index), and fatigue and pain (PROMIS Fatigue and Pain Interference measures). Results: Autonomic symptom burden was significantly and positively related to both history of COVID-19 infection and number of probable lifetime traumatic stressors, with probable lifetime traumatic stressors functioning as a positive moderator of the relationship between history of COVID-19 infection and autonomic symptom burden (Cohen's partial f 2  = .11, .07 and .02 for COVID history, trauma history and interaction term respectively, all p < .05, in a model also including age and gender). The moderation effect remained significant when adjusting for both current PTSD symptoms and pre-existing multi-system PASC-like symptoms prior to COVID-19. History of traumatic stress and of COVID-19 infection each had significant and positive associations with other PASC symptom domains, but with domain-specific patterns. Conclusions and Relevance: Prior history of traumatic stress has a positive and interactive effect on symptoms of autonomic dysregulation following COVID-19 infection, independent of PTSD symptoms. This suggests that exposure to traumatic stress may affect the response to future stressors, including physiologic stressors such as COVID-19 infection, through persistent changes in stress-threat response systems. This relationship may provide a physiologic explanation for prior observations that baseline anxiety prior to COVID-19 infection is associated with increased likelihood of PASC.


  • Moving towards a more naturalistic approach to evaluating drowsy driving risk

    by Catherine A McCall

    Catherine A McCall, MD; Moving towards a more naturalistic approach to evaluating drowsy driving risk, Sleep, , zsae139, https://doi.org/10.1093/sleep/zsae


  • Quasi-causal associations between chronotype and post-traumatic stress disorder symptoms: A twin study

    by Catherine A. McCall, Eric Turkheimer, Siny Tsang, Ally Avery, Glen E. Duncan, Nathaniel F. Watson


  • Open Access

    The relative contribution of COVID-19 infection versus COVID-19 related occupational stressors to insomnia in healthcare workers

    by Rebecca C. Hendrickson, Catherine A. McCall, Aaron F. Rosser, Kathleen F. Pagulayan, Bernard P. Chang, Ellen D. Sano, Ronald G. Thomas, Murray A. Raskind

    Objective/Background Healthcare workers have experienced high rates of psychiatric symptom burden and occupational attrition during the COVID-19 pandemic. Identifying contributory factors can inform prevention and mitigation measures. Here, we explore the potential contributions of occupational stressors vs COVID-19 infection to insomnia symptoms in US healthcare workers. Patients/Methods An online self-report survey was collected between September 2020 and July 2022 from N=594 US healthcare workers, with longitudinal follow-up up to 9 months. Assessments included the Insomnia Severity Index (ISI), the PTSD Checklist for DSM-5 (PCL-5), and a 13-item scale assessing COVID-19 related occupational stressors. Results Insomnia was common (45% of participants reported at least moderate and 9.2% reported severe symptoms at one or more timepoint) and significantly associated with difficulty completing work-related tasks, increased likelihood of occupational attrition, and thoughts of suicide or self-harm (all p<.0001). In multivariable regression with age, gender, and family COVID-19 history as covariates, past two-week COVID-related occupational stressors, peak COVID-related occupational stressors, and personal history of COVID-19 infection were all significantly related to past two-week ISI scores (β=1.7±0.14SE, β=0.08±0.03, and β=0.69±0.22 respectively). Although similar results were found for the PCL-5, when ISI and PCL-5 items were separated by factor, COVID-19 infection was significantly related only to the factor consisting of sleep-related items. Conclusions Both recent occupational stress and personal history of COVID-19 infection were significantly associated with insomnia in healthcare workers. These results suggest that both addressing occupational stressors and reducing rates of COVID-19 infection are important to protect healthcare workers and the healthcare workforce.

  • Open Access

    A Narrative Review of the Association between Post-Traumatic Stress Disorder and Obstructive Sleep Apnea

    by Catherine A. McCall, Nathaniel F. Watson

    Obstructive sleep apnea (OSA) and post-traumatic stress disorder (PTSD) are often co-morbid with implications for disease severity and treatment outcomes. OSA prevalence is higher in PTSD sufferers than in the general population, with a likely bidirectional effect of the two illnesses. There is substantial evidence to support the role that disturbed sleep may play in the pathophysiology of PTSD. Sleep disturbance associated with OSA may interfere with normal rapid eye movement (REM) functioning and thus worsen nightmares and sleep-related movements. Conversely, hyperarousal and hypervigilance symptoms of PTSD may lower the arousal threshold and thus increase the frequency of sleep fragmentation related to obstructive events. Treating OSA not only improves OSA symptoms, but also nightmares and daytime symptoms of PTSD. Evidence suggests that positive airway pressure (PAP) therapy reduces PTSD symptoms in a dose-dependent fashion, but also presents challenges to tolerance in the PTSD population. Alternative OSA treatments may be better tolerated and effective for improving both OSA and PTSD. Further research avenues will be introduced as we seek a better understanding of this complex relationship.


  • Open Access

    The impact of working during the Covid-19 pandemic on health care workers and first responders: mental health, function, and professional retention

    by Rebecca C. Hendrickson, Roisin A. Slevín, Bernard P. Chang, Ellen Sano, Catherine McCall, Murray A. Raskind

    Background The COVID-19 pandemic has greatly affected front line health care workers (HCW) and first responders (FR). The infection risk from SARS CoV-2, the high mortality of hospitalized COVID-19 patients and the duration of the pandemic have created sustained and often traumatic stressors affecting HCW and FR. Objectives To assess the relationship of COVID-19 stressor frequency scores to psychiatric rating scale scores amongst HCW and FR. To determine if psychiatric rating scale scores mediate stressor effects on perceived work function and likelihood of remaining in current occupation. Design Observational, self-report in a convenience sample. Participants 118 HCW and FR caring for COVID-19 patients in the United States. Main Measure COVID-19 related stressor frequencies were assessed using a 17-item questionnaire. Psychiatric symptoms were assessed with the PTSD Checklist 5 (PCL5), the Patient Health Questionnaire 9 (for depression) (PHQ9), the Insomnia Severity Index (ISI), and the General Anxiety Disorder 7 (GAD7). Key Results Stressor frequency scores correlated significantly with PCL5 scores (R=.57, pConclusions These results direct attention to recognizing potentially treatable psychiatric symptoms, particularly those of PTSD, in HCW and FR experiencing COVID-19 related stressors. They also suggest that mitigating COVID-19 related stressors when possible, such as by providing adequate personal protective equipment, can improve HCW and FR mental health, work function and retention in the health care work force. Detailed assessments of participants’ exposure to covid-19 related occupational stressors, current psychiatric symptoms, and self-reported occupational functioning and likelihood of remaining in their current field (functional outcomes). Assessment of the dose-response relationship between exposure to covid-19 related occupational stressors and current psychiatric symptoms and functional outcomes. Mediation analysis quantifying the potential for current psychiatric symptoms to mediate the relationship between exposure to covid-19 related occupational stressors and functional outcomes. Limitations: convenience sample, limited numbers of first responder participants


  • Open Access

    Therapeutic Strategies for Mitigating Driving Risk in Patients with Narcolepsy

    by Catherine A McCall, Nathaniel F Watson

    Narcolepsy is a central nervous system hypersomnia disorder characterized by uncontrollable episodes of daytime sleep, sleep state instability, and cataplexy (sudden loss of muscle tone precipitated by emotion). Individuals with narcolepsy report more frequent sleep-related crashes, near crashes, and drowsy driving than drivers with other sleep disorders. As such, evaluating risk of sleep-related crashes is of great importance for this patient population. There are no established guidelines for ensuring driving safety in patients with narcolepsy; however, many providers currently use a combination of subjective report, report of prior crashes or near-misses, report of previously falling asleep while driving, sleepiness screening tools, and maintenance of wakefulness testing (MWT) to determine risk. Driving simulator tests, though often unavailable to the clinician, provide data to support the use of MWT for evaluation of alertness in drivers with narcolepsy. Treatments such as modafinil may improve driving performance; however, the impact of other treatments such as stimulants and sodium oxybate on driving has not been extensively studied. Behavioral and lifestyle modifications may also reduce risk, including scheduled naps, driving only short distances, and avoiding driving after meals, sedating medications, and alcohol intake. Even with effective treatment, alertness in patients with narcolepsy may never reach that of normal drivers; however, studies have suggested that narcolepsy patients may be able to drive safely with appropriate limitations.